The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

GlaxoSmithKline is recalling one lot of SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) suspension for intramuscular injection packs consisting of 10 Doses (20 vials) per pack from lot# 9LH3Y. The scope of the recall includes Wholesalers, Distributors and Healthcare Providers.

Recalled product was shipped between October 12, 2020 and October 22, 2020. The full contents of the cartons from lot #9LH3Y are being recalled (antigen and adjuvant vials). The recall is a precautionary measure due to the potential for loss of integrity of the antigen vial, although a search of GSK's global adverse event database has not identified a safety signal for Shingrix lot #9LH3Y related to infections or lack of efficacy, events that could occur if there were a loss of integrity of the vial.

NDC	Product Description	Lot Number	Expiration Date
58160-823-11	10 vials containing Lyophilized gE Antigen Component (NDC 58160-828-03) and 10 vials containing Adjuvant Suspension Component (NDC 58160-829-03) 10 doses per package (20 vials total)	9LH3Y	February 2022